Medical devices, healthcare technology and the business of care
510(k) clearance · K262277

70 NeuGlide Catheter

Piraeus Medical, Inc. · Decision date Sep 4, 2026

FDA DECISIONK262277

What did the FDA decide?

FDA records K262277 as a 510(k) premarket notification, with a decision dated Sep 4, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Cardiovascular
Decision date
Sep 4, 2026

FDA source record

Regulatory record facts

Identifier
K262277
Regulatory pathway
510(k) premarket notification
Product code
QJP
Decision code
SESE
Decision date
Sep 4, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Catheter, Percutaneous, Neurovasculature.

Product code
QJP
FDA device class
2

FDA decision timeline

  1. K262277 received

    Application receipt date recorded by FDA.

  2. K262277 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code QJP

Product / regulatory recordCompanyPathwayDecision dateSource
Perfuze, Ltd.510(k) clearanceNov 5, 2026FDA
Stryker Neurovascular510(k) clearanceOct 9, 2026FDA
Alembic, LLC510(k) clearanceOct 6, 2026FDA
Cognition Medical Corp.510(k) clearanceOct 2, 2026FDA
Route 92 Medical, Inc.510(k) clearanceSep 16, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Piraeus Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Maple Grove, MN

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records